RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome
Apoptosis, necroptosis and pro-inflammatory NF-κB-dependent signaling are repressed by receptor-interacting serine/threonine-protein kinase 1 (RIPK1). A recent paper in <i>Immunity</i> describes a small molecule inducing the proteolytic degradation of RIPK1. In preclinical experiments, this RIPK1 inhibitor improved the anticancer efficacy of radiotherapy, immunotherapy (with PD-1 blockade) and radioimmunotherapy (with CTLA-4 blockade).
Authors
- Jonathan Pol (ORCID: https://orcid.org/0000-0002-8355-7562)
- Manuela Lizarralde-Guerrero (ORCID: https://orcid.org/0009-0004-0737-0941)
- Andrea Checcoli (ORCID: https://orcid.org/0000-0002-8290-6310)
- Guido Kroemer
Institutions
- Inserm (FR)
- Institut Universitaire de France (FR)
- Université Paris Cité (FR)
- Université Paris Sciences et Lettres (FR)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Sorbonne Université (FR)
- Centre de Recherche des Cordeliers (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Hôpital Européen (FR)
Publication Details
- Journal
- OncoImmunology
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1080/2162402x.2024.2425465
- Citations
- 3
- Primary Topic
- Cell death mechanisms and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.70
Funders
- Association pour la Recherche sur le Cancer
- Agence Nationale de la Recherche
- Fondation pour la Recherche Médicale
- Ligue Contre le Cancer
- Institut National Du Cancer